CHICAGO, June 25, 2018 (GLOBE NEWSWIRE) -- BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint human cardiac tissue – specifically, a human cardiac patch.

The scientific milestone was accomplished within days of the May opening of the Company’s new research facility at JLABS in Houston, and led by Dr. Ravi Birla, the Company’s Chief Science Officer. The successfully printed cardiac patch contains multiple cell types of which the human heart is made of, rather than just cardiomyocytes, and includes preliminary vascularization. Bioprinted 3D cardiac patches can be used in patients with acute heart failure to restore lost myocardial contractility. The Company was able to achieve this milestone in just a few days and much sooner than anticipated – published articles in scientific literature report bioprinted human cardiac patches require 6-8 months of development time. BIOLIFE4D will now turn its focus to other constructs like valves, blood vessels and a mini-heart as it seeks to progress to 3D bioprinting a full human heart.

“We are extremely excited to have achieved this milestone and to successfully demonstrate our ability to 3D print human cardiac tissue. When we began this process, we knew this would be a key step in validating our technology and scientific approach, so we are pleased to be able to have accomplished this so quickly,” said Birla. “We have always believed that our scientific approach, as well as the tremendous team we have assembled, positioned us for rapid scientific accomplishment. The speed at which we bioprinted 3D human cardiac patches, within days, is unheard of within the scientific community. These efforts clearly demonstrate our ability to bioprint human tissue and provide a clear and rapid pathway towards bioprinting human hearts.”

BIOLIFE4D’s innovative 3D bioprinting process provides the ability to reprogram a patient’s own (white) blood cells to iPS cells, and then to differentiate those iPS cells into different types of cardiac cells needed to 3D bioprint not only a cardiac patch but ultimately, a human heart viable for transplant. This means BIOLIFE4D can successfully 3D bioprint using cardiac cells derived from their own iPS cells to create living, viable constructs.

That ability is crucial as the Company seeks to disrupt how heart disease and other cardiac impairments are treated, particularly by improving the transplant process by eliminating the need for donor organs. Heart disease is the number one killer of men and women in the United States each year, yet countless individuals who need transplants are left waiting as there are not enough donors to meet demand.

“This is a tremendous time for BIOLIFE4D and we could not be prouder to have accomplished this scientific landmark in such a short period of time,” said Steven Morris, CEO, BIOLIFE4D. “From the beginning, our mission has been to utilize our technology to save lives. Today, we believe we are one step closer to ultimately achieving that goal.”

To see how BIOLIFE4D’s process starts with a patient’s own cells and ends with a functional human heart ready for transplant, please watch this video.

To learn more about BIOLIFE4D and to express interest in investing please watch this video or visit  https://biolife4d.com/invest/.

Securities are offered pursuant to a Regulation A+. Investors are encouraged to read the Offering Circular and exhibits and consult with their tax, legal, or financial professional prior to investing.

About BIOLIFE4D

BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at  biolife4d.com. Connect with us on social media on Twitter (@BIOLIFE4D), Facebook, LinkedIn, and Instagram.

Forward Looking Statements
We caution you that, whether or not expressly stated, certain statements made in this news release that reflect management's expectations regarding future events and economic performance are forward-looking in nature and, accordingly, are subject to risks and uncertainties. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

Media Contact
Matthew Bretzius
FischTank Marketing and PR
biolife4d@fischtankpr.com